Following the release of its first-quarter results and operational update, Clovis Oncology’s shares traded down sharply. According to data provided by S&P Global Market Intelligence, as of Thursday night they had fallen almost 27% week to date.

Clovis published 1Q results Wednesday morning and they weren’t what shareholders were yearning for. The inaugural quarter of the year saw the company take in just over $34.2 million on the top line.

That was comprised entirely of net product revenue for its Rubraca, which holds Food and Drug Administration approval for maintenance treatment of ovarian, fallopian tube, and primary peritoneal cancer. That number was down from first-quarter 2021’s tally of just over $38 million.

For the period, the biotech posted a net loss just short of $60.2 million ($0.44 per share), which bettered the year-ago deficit of over $66 million.

Both numbers didn’t quite meet analyst expectations. Those prognosticators were collectively modeling nearly $37 million on the top line, and $0.43 in per-share net loss.

As for the operational update, Clovis said that Rubraca achieved its primary endpoint of “significantly improved investigator-assessed progression-free survival (PFS) compared with placebo,” in a clinical trial as a monotherapy in first-line ovarian cancer treatment.

The company added that it’s expecting two additional top-line phase 3 trial readouts within the next year “with potential to address ovarian and prostate cancer patient populations.”

Clovis said that next month at an industry conference, it will present initial phase 1 clinical data for its FAP-2286. This is an investigational drug that targets fibroblast activation protein (FAP).

The company remains dependent on sales of Rubraca, which isn’t the only drug of its type currently on the market.